Developing a cool novel rapid RNA quantification technology for LNP and other formulations.

Advising the exec team about strategy and new market opportunities for their smart spectrometer - it measures UV/Vis spectra of cloudy liquids (https://www.cloudspec.co.nz/). They have already achieved success in quality attribute monitoring for wine production, but it will do much more...

Usefully simple but surprisingly sensitive analytical instrumentation for aerospace and engineering applications. Helping the company expand its markets and applications into Pharma and other industries,

Novel analytical insight into therapeutic nanoparticles for nanomedicines - liposomes, lipid nanoparticles and other sub-visible drug delivery vehicles used in RNA vaccines, oncology, cell and gene therapy and hard to drug diseases.

Responsible for delivery novel growth strategies and developing new areas of technology and business to expand Agilent's molecular spectroscopy business in biopharma and pharma. Created multi-million organic and inorganic investments through collaborations, co-creations and M&A activities.https://www.businesswire.com/news/home/20211216005476/en/Nicoya-Extends-Series-A-Financing-With-Additional-20m-to-Meet-Demand-of-Rapidly-Growing-Proteomics-Industryhttps://www.halolabs.com/2022/07/11/halo-labs-completes-6m-series-c-growth-financing/

Responsible for integrating the Cobalt pharma sales and business development into the Agilent sales network post-acquisition. Originated and developed new products and marketing strategy of Agilent's Raman products for the pharmaceutical industry. Cobalt was acquired by Agilent in July 2017 and became the Raman division of the molecular spectroscopy part of Agilent's Life Sciences and Applied Markets Group business unit.

Founder and company director of this successful analytical instrument business, which was purchased by Agilent Technologies for £40M in July 2017. Cobalt developed analytical products for pharmaceutical analysis and security screening.Focused on developing new pharmaceutical product ideas and business with an emphasis on strategy, sales and product marketing. Developed company branding/media, business development and marketing strategy. Founded the world's first seminar on transmission Raman spectroscopy, bringing together leaders from across the world applying transmission Raman in the pharma QC market.I managed the intellectual property portfolio, including competitor litigation proceedings. As a board member I was also heavily involved in the discussions and due diligence around the sale of Cobalt to Agilent.

Cobalt created instruments and technology for analysis of tablets and capsules, airport security liquids screening and for portable first-responder applications. It was acquired by Agilent Technologies in 2017 and became Agilent's Raman division. I was a founder and director serving on the board for the whole of the company's 9 years. Acted as sales and marketing director, intellectual property manager and product management.The company's inventions - Transmission Raman (TRS) and Spatially Offset Raman spectroscopy (SORS) - were novel technologies that added new capabilities to several markets. SORS allows identification of materials inside unopened opaque containers and TRS allows quantitative analysis of pharmaceutical dosage forms without wet chemistry or sample preparation. During this period in the company I was responsible for global sales and marketing and developing the company's sales infrastructure, including appointing and training a network of international distributors. I was responsible for identifying the markets for these new technologies and was the architect for new products and product management. This included two Pharma products, one called RapID - a unique capability for identifying raw materials through unopened non-transparent packaging for regulatory compliance needs. The first full year of sales attracted £1.2M direct business and it remains a unique high-value product in the Raman ID market and the only solution that can work through multi-layer paper sacks.

Cobalt (originally LiteThru Ltd.) was founded to bring unique technologies based on Raman spectroscopy to a number of different markets. These technologies were developed at STFC through publicly-funded research and the success of this company brought millions of pounds back to UK research. I was the acting CEO in this period and a company founder. I found investment for internal development of the technologies and negotiated the investment agreement and IP licences. I completed a round of £750K seed funding from VC and angel investors that started the company and enabled development of our first product, the TRS100. This was a new instrument development of a previously-unused technology in Pharmaceutical QC to quantify the components of intact pharmaceutical dosage forms for quality control. Key activities included turning customer requirements and user stories into the product definition.I also found a number of high-value bespoke projects, which were used to bootstrap the company's product developments and expansion, and avoided the need for further fund-raising in this period.

I was responsible for managing a portolio of around 200 patents and 60 families as the intellectual property manager for this public research organisation, which attracts funding of around £650M per year. I was the business contact for licensing IP to external organisations.One of my roles was as a business development manager, during which time I develop business opportunities for the novel technologies of spatially offset Raman spectroscopy and transmission Raman spectroscopy. These technologies became the building blocks that allowed me to found LiteThru/Cobalt Light Systems and raise the seed funding to spin this company out of STFC.

I was responsible for developing new technologies for the Enhanced Styling Category at Port Sunlight. This was a particularly inventive time with significant investment into fundamental research activities. I was involved in a collaboration with BASF's polymer division to create a new type of polymer for styling with enhanced style-stability targeting US and Japanese customers.I had a role in technology innovation and IP protection and benefitted from Unilever's excellent management development programme.

I was seconded to Nippon Lever, a Unilever technology development centre, to transfer a new technology from Unilever's research organisation in the UK to the Lux and Mod's styling brands in Japan. The new technology, based on a type of thermoplastic block co-polymer elastomer, was to be developed as an altenative to traditional technologies for styling products. I was responsible for developing and testing these formulations on consumers in Japan.